Michael Exton is Chief Executive Officer and Director of Lexicon Pharmaceuticals, Inc. (LXRX). The company reported total compensation of $3,553,953 for fiscal year 2025.
| Salary | $650,576 |
|---|---|
| Bonus | $483,822 |
| Stock awards | $1,049,304 |
| Option awards | $1,355,231 |
| Non-equity incentive plan | $0 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $15,020 |
| Total | $3,553,953 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Lexicon Pharmaceuticals, Inc. filed March 16, 2026, accession 0001062822-26-000056.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | Chief Executive Officer and Director | $650,576 | $483,822 | $1,049,304 | $1,355,231 | $0 | $0 | $15,020 | $3,553,953 |
| FY2024 | Chief Executive Officer and Director | $303,726 | $222,600 | $0 | $2,308,770 | $0 | $0 | $493 | $2,835,589 |
Totals as disclosed in each year's own compensation disclosure for Lexicon Pharmaceuticals, Inc..
| Peer-group chief executive median | $5,896,045 |
|---|---|
| Difference from that median | $-2,342,092 |
| Percentile within the disclosed peer group | 1st |
| Peers with a disclosed figure | 9 |
Medians and percentiles are computed across the peer group Lexicon Pharmaceuticals, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Michael Exton this page | Chief Executive Officer and Director | $3,553,953 |
| Craig Granowitz | Senior Vice President and Chief Medical Officer | $1,755,909 |
| Scott Coiante | Senior Vice President and Chief Financial Officer | $1,558,246 |
| Brian Crum | Senior Vice President and General Counsel | $1,500,384 |
| Wendy McDermott | Senior Vice President, Human Resources | $1,270,346 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Lexicon Pharmaceuticals, Inc. compensation brief.
Michael Exton's compensation sits inside Lexicon Pharmaceuticals, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.